Skip to main content

Advertisement

Table 2 Characteristics at follow-up of 273 patients included in the studya

From: Dysglycemia associations with adipose tissue among HIV-infected patients after 2 years of antiretroviral therapy in Mwanza: a follow-up cross-sectional study

Age at follow-up, year 41.5 (9.8) (Range 21–75)
Religion
 Christian 225 (82.4)
 Muslim 34 (12.5)
 No religion 14 (5.1)
Smoking status, n (%)
 Never 197 (72.2)
 Past 65 (23.8)
 Current 11 (4.0)
Alcohol drinking, n (%)b
 Never 108 (39.7)
 Past 133 (48.9)
 Current 31 (11.4)
Fruits and vegetables consumption per day, n (%)
 1–2 servings 81 (29.7)
 3–4 servings 79 (28.9)
  ≥ 5 servings 113 (41.4)
Time spent in vigorous physical activity per week (minutes), n (%)
 Inadequate (<75 min) 64 (23.4)
 Adequate (≥75 min) 209 (76.6)
Weight (kg) 52.8 (8.5)
Body mass index (kg/m2) 19.9 (2.8)
Nutritional status according to BMI categories, n (%)
 Undernourished (BMI < 18.50 kg/m2) 73 (26.7)
 Normal weight (BMI 18.50–24.99 kg/m2) 188 (68.9)
 Overweight (BMI 25.00–29.99 kg/m2) 10 (3.7)
 Obese (BMI ≥ 30.00 kg/m2) 2 (0.7)
Fat mass index (kg/m2)c 4.3 (2.4)
Fat-free mass index (kg/m2)c 15.5 (1.6)
Current antiretroviral therapy regimen, n (%)d
 AZT + 3TC + EFV 41 (15.8)
 AZT + 3TC + NVP 84 (32.3)
 TDF + FTC + EFV 70 (26.9)
 TDF + 3TC + EFV 65 (25.0)
Pre-diabetes, n (%)e 57 (20.8)
Diabetes Mellitus, n (%) 4 (1.5)
Pre-diabetes (IFG + IGT) and Diabetes Mellitus, n (%) 61 (22.3)
  1. AZT Zidovudine, 3TC Lamivudine, EFV Efavirenz, NVP Nevirapine, TDF Tenofovir, FTC Emtricitabine
  2. aData in mean(sd) or n (%)
  3. b272 patients included in analysis
  4. c269 patients included in analysis
  5. d260 patients included in analysis
  6. eImpaired Fasting Glucose (IFG) or Impaired Glucose Tolerance (IGT)